These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 8656445)

  • 1. Re:Randomized trial of adjuvant human interferon gamma versus observation in high-risk cutaneous melanoma: a Southwest Oncology Group study.
    Lollini PL; Nanni P; de Giovanni C; Nicoletti G; Landuzzi L
    J Natl Cancer Inst; 1996 Jul; 88(13):926-7. PubMed ID: 8656445
    [No Abstract]   [Full Text] [Related]  

  • 2. Randomized trial of adjuvant human interferon gamma versus observation in high-risk cutaneous melanoma: a Southwest Oncology Group study.
    Meyskens FL; Kopecky KJ; Taylor CW; Noyes RD; Tuthill RJ; Hersh EM; Feun LG; Doroshow JH; Flaherty LE; Sondak VK
    J Natl Cancer Inst; 1995 Nov; 87(22):1710-3. PubMed ID: 7473820
    [No Abstract]   [Full Text] [Related]  

  • 3. Systematic review of systemic adjuvant therapy for patients at high risk for recurrent melanoma.
    Verma S; Quirt I; McCready D; Bak K; Charette M; Iscoe N
    Cancer; 2006 Apr; 106(7):1431-42. PubMed ID: 16511841
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant interferon therapy for melanoma: high-dose, low-dose, no dose, which dose?
    Schuchter LM
    J Clin Oncol; 2004 Jan; 22(1):7-10. PubMed ID: 14665612
    [No Abstract]   [Full Text] [Related]  

  • 5. Management of cutaneous melanoma.
    Tsao H; Atkins MB; Sober AJ
    N Engl J Med; 2004 Sep; 351(10):998-1012. PubMed ID: 15342808
    [No Abstract]   [Full Text] [Related]  

  • 6. Current therapy of cutaneous melanoma.
    Mays SR; Nelson BR
    Cutis; 1999 May; 63(5):293-8. PubMed ID: 10349545
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant interferon in melanoma - a resurrection?
    Middleton MR; Thatcher N
    Br J Cancer; 2001 May; 84(9):1141-2. PubMed ID: 11336461
    [No Abstract]   [Full Text] [Related]  

  • 8. Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis.
    Mocellin S; Pasquali S; Rossi CR; Nitti D
    J Natl Cancer Inst; 2010 Apr; 102(7):493-501. PubMed ID: 20179267
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Update on adjuvant interferon therapy for high-risk melanoma.
    Agarwala SS; Kirkwood JM
    Oncology (Williston Park); 2002 Sep; 16(9):1177-87; discussion 1190-2, 1197. PubMed ID: 12380946
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Present status and future prospects for adjuvant therapy of melanoma: time to build upon the foundation of high-dose interferon alfa-2b.
    Moschos SJ; Kirkwood JM; Konstantinopoulos PA
    J Clin Oncol; 2004 Jan; 22(1):11-4. PubMed ID: 14665613
    [No Abstract]   [Full Text] [Related]  

  • 11. Adjuvant therapy in melanoma.
    Mohr P; Weichenthal M; Hauschild A
    Onkologie; 2003 Jun; 26(3):227-33. PubMed ID: 12845206
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [After removal of a malignant melanoma. Enhancing the immune system!].
    MMW Fortschr Med; 1999 Nov; 141(44):66. PubMed ID: 10912153
    [No Abstract]   [Full Text] [Related]  

  • 13. Adjuvant therapy for malignant melanoma.
    Stoutenburg JP; Schrope B; Kaufman HL
    Expert Rev Anticancer Ther; 2004 Oct; 4(5):823-35. PubMed ID: 15485316
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma.
    Hancock BW; Wheatley K; Harris S; Ives N; Harrison G; Horsman JM; Middleton MR; Thatcher N; Lorigan PC; Marsden JR; Burrows L; Gore M
    J Clin Oncol; 2004 Jan; 22(1):53-61. PubMed ID: 14665609
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Final Results of the Sunbelt Melanoma Trial: A Multi-Institutional Prospective Randomized Phase III Study Evaluating the Role of Adjuvant High-Dose Interferon Alfa-2b and Completion Lymph Node Dissection for Patients Staged by Sentinel Lymph Node Biopsy.
    McMasters KM; Egger ME; Edwards MJ; Ross MI; Reintgen DS; Noyes RD; Martin RC; Goydos JS; Beitsch PD; Urist MM; Ariyan S; Sussman JJ; Davidson BS; Gershenwald JE; Hagendoorn LJ; Stromberg AJ; Scoggins CR
    J Clin Oncol; 2016 Apr; 34(10):1079-86. PubMed ID: 26858331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjuvant therapy for melanoma.
    Sondak VK
    Cancer J; 2001; 7 Suppl 1():S24-7. PubMed ID: 11504282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Node positive melanoma--a positive note?
    Kelly J; Kerin MJ
    Surgeon; 2012 Apr; 10(2):63-4. PubMed ID: 22385525
    [No Abstract]   [Full Text] [Related]  

  • 18. How melanoma is treated in real life.
    Dummer R; Schadendorf D
    Arch Dermatol; 2008 May; 144(5):664-5. PubMed ID: 18490596
    [No Abstract]   [Full Text] [Related]  

  • 19. The role of adjuvant interferon in high risk melanoma patients.
    Dermatol Surg; 2000 Jun; 26(6):607-8. PubMed ID: 10848951
    [No Abstract]   [Full Text] [Related]  

  • 20. Duration of high-dose interferon alpha-2b regimen for resected high-risk melanoma.
    Agarwala SS; Gray RJ; Wong MK
    J Clin Oncol; 2009 Sep; 27(25):e82-3; author reply e84. PubMed ID: 19635995
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.